MONTREAL, April 28,
2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB:
VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, today announced the results of the
proposals submitted to shareholders at its annual meeting of
shareholders held on April 27, 2023
(the "Meeting").
Election of Directors
The results of the vote for those elected as directors are as
follows:
Nominees
|
Votes
For
|
Votes
Against
|
|
Number of
Shares
|
%
|
Number of
Shares
|
%
|
Steve Saviuk
|
30,736,915
|
97.28
|
859,400
|
2.72
|
Richard
MacKay
|
30,737,015
|
97.28
|
859,300
|
2.72
|
Marc Léger
|
30,737,015
|
97.28
|
859,300
|
2.72
|
Maureen
Brennan
|
31,423,715
|
99.45
|
172,600
|
0.55
|
Michel
Trudeau
|
31,417,005
|
99.43
|
179,310
|
0.57
|
Stuart W.
Fowler
|
31,448,115
|
99.53
|
148,200
|
0.47
|
Apppointment of the auditor
The results of the vote for the appointment of
PricewaterhouseCoopers LLP as the auditor for Valeo are as
follows:
|
Votes
For
|
Votes
Against
|
|
Number of
Shares
|
%
|
Number of
Shares
|
%
|
|
31,694,761
|
100
|
0
|
0.00
|
Appointments
Following the Meeting, the following appointments were made by
the newly elected board of directors of Valeo (the
"Board"):
Chairman of the Board: Richard
D. MacKay
Audit Committee Chairman: Michel Trudeau
Audit Committee Members: Marc Léger, Stuart Fowler
Corporate Governance and Human Resources Committee
Chairman: Marc Léger
Corporate Governance and Human Resources Committee
Members: Maureen C. Brennan
and Steve Saviuk
In addition, the Board is pleased to announce the appointment of
Stuart W. Fowler as director of the
Company. The Board also announced the departure of Messrs.
Vincent P. Hogue and Frederic Fasano as directors of the Company.
"I am pleased to welcome Stuart to our Board of Directors.
Stuart is a well known senior executive in the Canadian
pharmaceutical industry having been President and General
Manager of Alcon Canada and
President and General Manager of Allergan Canada. We look
forward to his strategic insight and guidance in both
the field of ophthalmology and the broader pharmaceutical industry
", said Steve Saviuk, Valeo's Chief
Executive Officer. "We would also like to extend our most
sincere thanks to our outgoing Board members, Vincent Hogue and Frederic Fasano for their contributions and
invaluable service over the years. We appreciate the time,
knowledge and expertise they both have provided the Company and
wish them the very best".
About Valeo Pharma
Valeo Pharma is a fast growing Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.